跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT06959628
NCT06959628招募中不适用

Study on the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined With Introducer Sets for Cerebral Protection During Carotid Angioplasty

Shenzhen Wecan Medical Technology Co.,Ltd1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2024年7月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
15
试验地点
1
主要终点
The composite incidence of death, stroke, and myocardial infarction within 30 days postoperatively.
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of the study is to evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty

详细描述

The physician shall strictly follow the clinical study protocol and shall not deviate from or substantially change the protocol. However, in case of emergency such as immediate risk to the subjects, which needs tobe eliminated immediately, it may be reported in written form afterwards. During the course of the study,documents such as amendments to the clinical study protocol and informed consent, requests for deviation,and resumption of the suspended clinical study shall be subject to the written approval of the Ethics Committee

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥ 18 years;
  • •Patients with internal carotid artery stenosis, meeting at least one of the following conditions:
  • •Asymptomatic carotid artery stenosis: Stenosis severity > 70%;
  • •Symptomatic carotid artery stenosis: Stenosis severity > 50%, with one or more of the following symptoms occurring within 180 days prior to the procedure: transient ischemic attack (TIA), transient visual obscurations (TVO), or mild/non-disabling stroke;
  • •Common carotid artery diameter > 6 mm, and meets the required vascular diameter for carotid artery stenting;
  • •The participant or their legal guardian is able to understand the purpose of the trial, voluntarily consent to participation, sign an informed consent form, and is willing to comply with follow-up requirements as outlined in the study protocol.

排除标准

  • •Anatomical Exclusion Criteria:
  • •Patients with extensive atherosclerotic plaques in the proximal common carotid artery, which hinder safe surgical manipulation;
  • •Patients with lesions in the common carotid artery access area or its proximal segment;
  • •Patients with the common carotid artery bifurcation located < 5 cm from the clavicular margin;
  • •Patients with tandem severe stenosis or occlusion at the target lesion site;
  • •Patients who have previously received stent or graft implantation in the ipsilateral carotid artery;
  • •Patients with bilateral carotid artery stenosis requiring intervention on both sides;
  • •Patients with acute or subacute thrombosis, arteriovenous malformations, or other abnormal vascular structures in the target lesion or adjacent regions;
  • •Patients with severe calcification or tortuosity at the target lesion site, making it difficult to deliver devices to the intended location;
  • •Patients with concomitant severe symptomatic stenosis in other vascular territories, including intracranial or extracranial arteries;
  • •Patients who have experienced an ischemic stroke within the past 3 months, which may impact endpoint evaluation;
  • •Patients with a history of spontaneous intracranial hemorrhage within the past 12 months;
  • •Patients diagnosed with carotid artery dissection;
  • •Patients with carotid stenosis due to non-atherosclerotic causes;
  • •Patients with other cardiovascular conditions that may predispose to embolism, including left ventricular aneurysm, cardiomyopathy, mechanical aortic or mitral valves, infective endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma;
  • •Patients with central nervous system disorders, including cranial nerve impairment, which could confound endpoint evaluation (e.g., severe dementia, secondary epilepsy, etc.);
  • •Patients with chronic atrial fibrillation;
  • •Patients with paroxysmal atrial fibrillation episodes within the past 6 months or those requiring long-term anticoagulation therapy due to paroxysmal atrial fibrillation;
  • •Patients who have had a myocardial infarction within the last 6 months;
  • •Patients who have undergone or plan to undergo coronary artery bypass grafting (CABG), endovascular stenting procedures, or heart valve surgeries within 90 days prior to the procedure, which may interfere with endpoint evaluation;
  • •Patients with active bleeding tendencies or significant coagulation disorders;
  • •Patients with a history of gastrointestinal bleeding that could interfere with antiplatelet therapy;
  • •Patients with preoperative liver or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 5 times the upper limit of normal, or serum creatinine (Cr) > 3.0 mg/dL (265.2 μmol/L);
  • •Patients with known hypersensitivity to contrast agents, anticoagulants, antiplatelet medications, or materials used in stent delivery systems (e.g., nitinol, PTFE, nylon-based polymers);
  • •Patients with intracranial or other malignancies;
  • •Patients with a life expectancy of less than 3 years;
  • •Women who are planning pregnancy, pregnant, or breastfeeding;
  • •Patients participating in another clinical trial or those who have not withdrawn or been excluded from a trial within the last 3 months of the screening period;
  • •Other patients who, in the investigator's opinion, are deemed unsuitable for inclusion in the study

研究组 & 干预措施

Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets

Experimental

Device systems for the treatment of carotid artery stenosis

干预措施: Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets (Device)

结局指标

主要结局

The composite incidence of death, stroke, and myocardial infarction within 30 days postoperatively.

时间窗: Within 30 days after procedure

Composite incidence is the rate of occurrence of a composite endpoint, which is a combination of multiple study outcomes.

次要结局

  • Immediate technical success rate(intraoperative)
  • The incidence of stroke(pre-discharge (up to 14 days) and 30 days post-surgery)
  • The incidence of neurological injury(Within 24 hours post-surgery and 30 days post-surgery)
  • The incidence of myocardial infarction(pre-discharge (up to 14 days) and 30 days post-surgery)
  • All-cause mortality during perioperative period (from surgery to 30 days after surgery)(Intraoperatively, pre-discharge (up to 14 days) and 30 days post-surgery)
  • Delivery system-related complications during perioperative period (from surgery to 30 days after surgery)(Intraoperatively, pre-discharge (up to 14 days) and 30 days post-surgery])

研究者

发起方
Shenzhen Wecan Medical Technology Co.,Ltd
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Study on the Trans-Carotid Artery Occlusion Shunt SystemRevascularizationCarotid Artery StenosisCarotid Artery Diseases
NCT06924593Shenzhen Wecan Medical Technology Co.,Ltd162
已完成
不适用
Study on the Trans-Carotid Artery Occlusion Shunt System Combined With Introducer SetsCarotid Artery StenosisCarotid Artery Diseases
NCT06864299Shenzhen Wecan Medical Technology Co.,Ltd15
进行中（未招募）
不适用
PrizValve® Transcatheter Aortic Valve Replacement StudyAortic Valve Stenosis
NCT04836897Shanghai NewMed Medical Co., Ltd.120
招募中
不适用
Valveclip® Transcatheter Mitral Valve Repair StudyMitral Regurgitation
NCT05021614Shanghai NewMed Medical Co., Ltd.150
已完成
不适用
Transcatheter Aortic Valve Intervention-Live TransmissionAortic Valve Disorder
NCT01353287Medstar Health Research Institute110